Cargando…

Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions

Cardiomyopathies may be hereditary and associated with a familial predilection. Morbidity and mortality can be caused by heart failure, sudden death, or arrhythmias. Sometimes these events are the first manifestations of cardiovascular disease. Hypertrophic cardiomyopathy and arrhythmogenic cardiomy...

Descripción completa

Detalles Bibliográficos
Autores principales: Couto, José F., Martins, Elisabete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380898/
https://www.ncbi.nlm.nih.gov/pubmed/37510821
http://dx.doi.org/10.3390/jcm12144706
_version_ 1785080309020098560
author Couto, José F.
Martins, Elisabete
author_facet Couto, José F.
Martins, Elisabete
author_sort Couto, José F.
collection PubMed
description Cardiomyopathies may be hereditary and associated with a familial predilection. Morbidity and mortality can be caused by heart failure, sudden death, or arrhythmias. Sometimes these events are the first manifestations of cardiovascular disease. Hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy are perhaps most thoroughly studied in that context. Dilated cardiomyopathy, although most frequently of secondary etiology, has a significant familial cluster. Noncompaction of the left ventricle can sometimes be seen in healthy individuals and, in other instances, is associated with severe LV dysfunction. Genetic testing is of utmost importance, since it might allow for the identification of individuals carrying mutations predisposing them to these diseases. In addition, certain variants may benefit from tailored therapeutic regimens, and thus searching for a causal mutation can impact clinical practice and is recommended for all patients with HCM or ACM. Patients with DCM and positive family history should be included as well. Regular follow-ups are advised, even in those with negative phenotypes, because these disorders are often age dependent. During pregnancy and in the case of athletes, special consideration should be made as well. We intend to summarize the most current evidence regarding their management.
format Online
Article
Text
id pubmed-10380898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103808982023-07-29 Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions Couto, José F. Martins, Elisabete J Clin Med Review Cardiomyopathies may be hereditary and associated with a familial predilection. Morbidity and mortality can be caused by heart failure, sudden death, or arrhythmias. Sometimes these events are the first manifestations of cardiovascular disease. Hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy are perhaps most thoroughly studied in that context. Dilated cardiomyopathy, although most frequently of secondary etiology, has a significant familial cluster. Noncompaction of the left ventricle can sometimes be seen in healthy individuals and, in other instances, is associated with severe LV dysfunction. Genetic testing is of utmost importance, since it might allow for the identification of individuals carrying mutations predisposing them to these diseases. In addition, certain variants may benefit from tailored therapeutic regimens, and thus searching for a causal mutation can impact clinical practice and is recommended for all patients with HCM or ACM. Patients with DCM and positive family history should be included as well. Regular follow-ups are advised, even in those with negative phenotypes, because these disorders are often age dependent. During pregnancy and in the case of athletes, special consideration should be made as well. We intend to summarize the most current evidence regarding their management. MDPI 2023-07-15 /pmc/articles/PMC10380898/ /pubmed/37510821 http://dx.doi.org/10.3390/jcm12144706 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Couto, José F.
Martins, Elisabete
Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
title Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
title_full Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
title_fullStr Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
title_full_unstemmed Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
title_short Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
title_sort recommendations for the management of cardiomyopathy mutation carriers: evidence, doubts, and intentions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380898/
https://www.ncbi.nlm.nih.gov/pubmed/37510821
http://dx.doi.org/10.3390/jcm12144706
work_keys_str_mv AT coutojosef recommendationsforthemanagementofcardiomyopathymutationcarriersevidencedoubtsandintentions
AT martinselisabete recommendationsforthemanagementofcardiomyopathymutationcarriersevidencedoubtsandintentions